Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 7Cyclophosphamide 5Metformin 4durvalumab 3Vincristine 3Radiation 3Imiquimod 3Fluorouracil 3antitumor A 2Testosterone 2Surveys and Questionnaires 2Rituximab 2Prednisone 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Lapatinib 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Cisplatin 2Biopsy 2xentuzumab 1tremelimumab 1ribociclib 1posaconazole 1pexidartinib 1perflutren 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡